###begin article-title 0
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 407 411 <span type="species:ncbi:10090">mice</span>
Cyclooxygenases (COX) -1 and -2 are key mediators of the inflammatory response in the central nervous system. Since COX-2 is inducible by inflammatory stimuli, it has been traditionally considered as the most appropriate target for anti-inflammatory drugs. However, the specific roles of COX-1 and COX-2 in modulating a neuroinflammatory response are unclear. Recently, we demonstrated that COX-1 deficient mice show decreased neuroinflammatory response and neuronal damage in response to lipopolysaccharide (LPS).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 209 212 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 234 237 233 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 261 265 260 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
In this study, we investigated the role of COX-2 in the neuroinflammatory response to intracerebroventricular-injected LPS (5 mug), a model of direct activation of innate immunity, using COX-2 deficient (COX-2-/-) and wild type (COX-2+/+) mice, as well as COX-2+/+ mice pretreated for 6 weeks with celecoxib, a COX-2 selective inhibitor.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 44 48 44 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 301 305 298 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox</sup>
###xml 405 409 402 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 457 461 454 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 516 520 513 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
Twenty-four hours after LPS injection, COX-2-/- mice showed increased neuronal damage, glial cell activation, mRNA and protein expression of markers of inflammation and oxidative stress, such as cytokines, chemokines, iNOS and NADPH oxidase. Brain protein levels of IL-1beta, NADPH oxidase subunit p67phox, and phosphorylated-signal transducer and activator of transcription 3 (STAT3) were higher in COX-2-/- and in celecoxib-treated mice, compared to COX-2+/+ mice. The increased neuroinflammatory response in COX-2-/- mice was likely mediated by the upregulation of STAT3 and suppressor of cytokine signaling 3 (SOCS3).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
These results show that inhibiting COX-2 activity can exacerbate the inflammatory response to LPS, possibly by increasing glial cells activation and upregulating the STAT3 and SOCS3 pathways in the brain.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 216 218 216 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 222 223 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 259 260 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 659 660 659 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 960 961 960 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 962 963 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1143 1144 1143 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1145 1146 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 949 954 <span type="species:ncbi:9606">human</span>
Prostaglandin endoperoxide synthases or cyclooxygenases (COX-1 and COX-2) play a central role in the inflammatory cascade by converting arachidonic acid (AA), released from membrane phospholipids by a phospholipase A2 (PLA2), into prostaglandin endoperoxide H2, which in turn is converted to bioactive prostanoids by specific terminal synthases. The two COX isoforms share 60% homology in their amino acids sequence and have comparable kinetics; however they also show individual differences. COX-1 is normally constitutively expressed in most tissues and thought to be involved in homeostasis, whereas COX-2 is inducible upon inflammatory and other stimuli [1]. However, in the central nervous system (CNS), COX-1 and COX-2 are both constitutively expressed and COX-2 is mainly detected in the perinuclear, dendritic and axonal domains of neurons, particularly in cortex, hippocampus, amygdala and dorsal horn of the spinal cord of both rodent and human CNS [2-4]. In the CNS, COX-2 has been implicated in important physiological functions such as synaptic transmission, neurotransmitter release, blood flow regulation, and sleep/wake cycle [5-9].
###end p 11
###begin p 12
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 779 782 779 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1132 1134 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 784 788 <span type="species:ncbi:10090">mice</span>
Both COX-1 and COX-2 have been shown to play important roles in an inflammatory response, their contribution being different depending on the type of insult, the time after insult, and the tissue examined [6,10]. Because COX-2 is highly inducible by inflammatory stimuli it has been traditionally considered as the most appropriate target for anti-inflammatory drugs [2,11]. However, the exact role of each COX isoform in neuroinflammation is unclear. While we have recently reported that genetic deletion or pharmacological inhibition of COX-1 significantly ameliorate the neuroinflammatory response and brain injury following lipopolysaccharide (LPS) treatment [12], the role of COX-2 in the neuroinflammatory process remains controversial. For instance, COX-2 deficient (COX-2-/-) mice have been reported to be resistant to the febrile response induced by peripheral injection of LPS [13]. On the other hand, selective pharmacological inhibition of COX-2, but not of COX-1, increases the expression of several pro-inflammatory genes in the vascular associated cells and the parenchymal microglia after systemic injection of LPS [14].
###end p 12
###begin p 13
###xml 65 69 65 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 89 92 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
In this study we examined the neuroinflammatory response of COX-2-/- and wild type (COX-2+/+) mice to intracerebroventricular (icv) injection of LPS, which is a model of direct activation of brain innate immunity [15-19].
###end p 13
###begin p 14
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 546 550 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 727 729 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 937 939 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 940 942 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 992 994 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 995 997 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 998 1000 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1231 1233 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
LPS, a component of the outer cell wall of gram-negative bacteria, mediates its effect through the CD14 receptor, a glycosylphosphatidylinositol-linked membrane protein that is present on microglial cells. The LPS-CD14 complex, together with other adaptor proteins, binds to the toll-like receptor 4 (TLR4), which is present on microglia, but not on astrocytes, oligodendrocytes or cortical neurons [20]. This initiates a bifurcated signal transduction cascade that leads to the transcription of inflammatory and immune response genes, primarily via nuclear factor- kappaB (NF-kappaB) activation but also through c-Fos/c-Jun and Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3)-dependent pathways [21]. The signaling events ultimately lead to the production of free radicals generated by NADPH oxidase, myeloperoxidase and inducible nitric oxide synthase (iNOS) in combination with cytokines and chemokines [22,23], which are mediators of the LPS-induced injury [15,16,24]. In this regard, previous data suggest that interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) can contribute to neuronal death in models of acute CNS injury as well as in chronic neurodegenerative disease [25].
###end p 14
###begin p 15
###xml 40 44 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 80 84 80 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 457 461 457 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
In this study, we demonstrate that COX-2-/- mice are more susceptible than COX-2+/+ mice to LPS-induced neuronal injury and exhibit an increase in microglia and astrocyte activation, and increases in the expression of genes and proteins for inflammatory cytokines, chemokines, reactive oxygen species-generating enzymes, such as iNOS and NADPH oxidase, and in the expression of STAT3 and suppressor of cytokine signaling 3 (SOCS3) signaling molecules. COX-2+/+ mice chronically treated with celecoxib, a COX-2 selective inhibitor, also exhibit an increased neuroinflammatory response compared to untreated wild-type mice.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Animals housing
###end title 17
###begin p 18
###xml 26 30 26 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 39 43 39 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 751 755 745 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 896 898 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 104 108 <span type="species:ncbi:10090">Mice</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">Mice</span>
###xml 755 759 <span type="species:ncbi:10090">mice</span>
Three-month-old male COX-2+/+ and COX-2-/- mice on a C57BL/6-129/Ola genetic background were used [26]. Mice were received at our animal facility at 6 weeks of age from a NIEHS colony maintained by Taconic Farms (Germantown, NY) with heterozygous by heterozygous breedings for greater than 35 generations. In order to prevent the inclusion of strain or genetic background confounders between COX deficient and wild type mice, all of the mice used in this study were progeny derived from heterozygous by heterozygous mating and therefore all contained the same strain and genetic background [26,27]. Mice were housed at 25degreesC in our animal facility with a 12 h light/dark cycle with free access to food and water. For celecoxib pretreatment, COX-2+/+ mice were given free access for six weeks to a diet containing 0 or 6000 ppm celecoxib, a COX-2 specific inhibitor, as previously described [28]. Briefly, celecoxib (Celebrextrade mark) capsules (400 mg; Pfizer Inc, New York, NY) were obtained from the NIH Division of Veterinary Medicine and were incorporated into feed by Research Diets, Inc. (New Brunswick, NJ). All procedures were performed under a NICHD approved animal protocol in accordance with NIH guidelines on the care and use of laboratory animals.
###end p 18
###begin title 19
LPS administration
###end title 19
###begin p 20
###xml 204 212 203 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 600 602 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 603 605 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 606 608 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 751 753 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 204 211 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg, i.p.) and positioned in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA). Vehicle (sterile phosphate buffer, 5 mul) or LPS (E. coli serotype 055:B5 (Sigma); 5 mug in 5 mul of sterile saline) was administered into the cerebral lateral ventricle using a 10 mul syringe with a 33 gauge needle (World Precision Instruments, Sarasota, FL) and a syringe pump (Stoelting, Wood Dale, IL) at a rate of 1 mul/min. This dose of LPS has been shown by us and by others to produce significant neuroinflammation when measured at 24 h [12,24,29]. The coordinates for the sterotaxic injections were -2.3 mm dorsal/ventral, -1.0 mm lateral, and -0.5 mm anterior/posterior from the bregma [30]. The needle was kept in this position for an additional 5 min after injection and then retrieved slowly from the brain.
###end p 20
###begin title 21
Tissue preparation and histology
###end title 21
###begin p 22
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Twenty-four hours after LPS injection, mice were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and then rapidly perfused transcardially with 0.9% saline solution containing 0.5% sodium nitrate and heparin (10 U/ml), followed by ice cold 4% paraformaldehyde in 0.1 M phosphate buffer. After transcardiac perfusions, brains were rapidly removed, postfixed for 4 h, and then cryoprotected in 30% sucrose at 4degreesC. Frozen brains were cut into 30 mum coronal sections using a cryostat and stored at -20degreesC.
###end p 22
###begin p 23
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Neurodegeneration was assessed using Fluoro-Jade B (FJB), as previously described [31]. Briefly, mounted brain sections were dried for 4 h, rehydrated through graded concentrations of alcohol (100, 70%; 1 min each), and rinsed for 1 min in distilled water. Sections were dipped and shaken in potassium permanganate (0.06%) for 20 min, rinsed for 1 min in distilled water, dipped, and shaken in a solution containing 0.004% FJB (Histochem, Jefferson, AR), 0.1% acetic acid for 20 min. The slides were thereafter rinsed three times in distilled water (1 min each), dried, dipped in xylene, and coverslipped with Permount mounting medium (Fisher Scientific, Ottawa, Ontario) [31].
###end p 23
###begin p 24
###xml 445 450 <span type="species:ncbi:10090">mouse</span>
For immunohistochemistry, free-floating sections were rinsed three times in phosphate-buffered saline (PBS) (10 min each) and then pretreated with PBS containing 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity. After PBS wash, brain sections were incubated once in PBS with 0.3% Triton X-100 and once in PBS containing 0.5% BSA for 30 min with gentle shaking. The sections were incubated overnight at 4degreesC with anti-mouse scavenger receptor A (SRA) (1:100; Serotec, Raleigh, NC) in PBS containing 5% normal serum; followed by treatment with a biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) for 1 h in PBS plus 5% normal serum at room temperature, and then with the Vector ABC kit (Vector Laboratories) for 1 h at room temperature. The sections were visualized with the 3,3-diaminobenzidine tetrachloride (DAB; Vector Laboratories, Burlingame, CA). Mounted brain sections were dried for 4 h, dehydrated through graded concentration of alcohol, cleared in xylene, and coverslipped with Permount mounting medium (Fisher Scientific).
###end p 24
###begin title 25
RNA extraction and quantitative real-time PCR
###end title 25
###begin p 26
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 758 763 747 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 770 774 759 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox</sup>
###xml 789 790 778 779 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 867 871 852 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 981 983 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1139 1143 1114 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1143 1147 <span type="species:ncbi:10090">mice</span>
Brain total RNA was extracted using RNeasy Lipid Tissue Midi Kit (Qiagen, Valencia, CA, USA) as directed by the manufacturer. Total RNA extraction and reverse transcription were performed as previously described, using the Applied Biosystems Assay-On-Demand Gene Expression protocol with an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) [32-34]. Briefly, five micrograms of total RNA were reverse transcribed using a High Capacity cDNA Archive kit (Applied Biosystems). Quantitative PCR for glial fibrillary acidic protein (GFAP), SRA1, TNF-alpha, IL-1beta, interleukin 6 (IL-6), CCL2/monocyte chemoattractant protein-1 (MCP-1), CCL3/macrophage inflammatory protein 1 alpha (MIP-1alpha), iNOS, the NADPH oxidase subunits gp91phox and p67phox, mPGES-1, cPLA2, COX-1, NF-kappaB-P65, STAT3, and SOCS3, was performed using specific Taqman(R) probes (Applied Biosystems). Data were analyzed using the comparative threshold cycle (DeltaDelta Ct) method [35]. Results were normalized with phosphoglycerate kinase 1 (Pgk1) as the endogenous control, and expressed as fold difference from the vehicle injected COX-2+/+ mice.
###end p 26
###begin title 27
Western blotting
###end title 27
###begin p 28
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 403 408 403 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 911 913 907 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 1163 1167 1142 1144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1008 1013 <span type="species:ncbi:10090">mouse</span>
Western blot analyses were carried out as described previously [33] and nuclear proteins were prepared by using a compartmental protein extraction kit (Chemicon, Temecula) according to the manufacturer's protocol. Briefly, protein fractions were separated on Criterion gels (Bio-Rad), blotted onto a polyvinylidene difluoride membrane (Bio-Rad), and then immunoblotted with antibodies that recognize p67phox (1:500; BD Biosciences), phosphorylated STAT3 (p-STAT3 (Tyr 705), 1:500, Cell signaling, USA), STAT3 (1:1000 Cell signaling, USA), COX-1 (1:500 Cayman Chemicals, USA), and glyceraldehyde dehydrogenase (GAPDH, 1: 2000, Santa Cruz, CA, USA) to control for protein loading. Blotted proteins were detected and quantified using an Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NB, U.S.A.). For IL-1beta measurement, a 500 mul aliquot of the crude brain homogenate was centrifuged at 10,000 x g for 20 min at 4degreesC, and the supernatant was immediately assayed using an ELISA-based kit (mouse IL-1beta/IL-1F2 Quantikine ELISA kit, R&D Biosystems, Minneapolis, USA). TNF-alpha and MIP-1alpha were measured in the brain supernatant (Searchlight(R) Sample testing service, Pierce Biotechnology, Woburn, MA, USA). Results were expressed as ng/g protein.
###end p 28
###begin title 29
Statistics
###end title 29
###begin p 30
Data were expressed as mean +/- SEM and were analyzed with a two-way ANOVA. For Real-Time PCR results, the two-way ANOVA was performed on the log-transformed DeltaDeltaCt. p values < 0.05 were considered statistically significant.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
###xml 10 14 10 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
Only COX-2-/- mice show FluorojadeB positive neurons 24 h after LPS
###end title 32
###begin p 33
###xml 83 87 83 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 96 100 96 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 271 275 271 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 478 482 478 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
To address the hypothesis that LPS exerts different neurotoxic effects in the COX-2+/+ and COX-2-/- mice, we assessed neuronal damage in the brain 24 h after LPS injection using the fluorescent marker FJB, which selectively stains injured neurons [31]. LPS-injected COX-2-/- mice (Fig. 1) showed FJB-positive cells in the hippocampal area. In contrast, FJB-positive neurons were not detected in the hippocampus of vehicle-injected mice of each genotype and in LPS injected COX-2+/+ mice.
###end p 33
###begin p 34
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of COX-2 deficiency on LPS-induced neuronal degeneration.</bold>
###xml 150 154 150 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 163 167 163 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 393 397 393 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 397 401 <span type="species:ncbi:10090">mice</span>
Effects of COX-2 deficiency on LPS-induced neuronal degeneration. Representative photomicrographs of FluoroJade-B staining in the hippocampus of COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. High magnification (10x) images of FluoroJade-B staining in the hippocampus are shown. The inset shows details of the neurons stained by FluoroJade-B in the hippocampus of COX-2-/- mice 24 h after icv injection of LPS (40x magnification). Bars represent 100 mum.
###end p 34
###begin title 35
###xml 55 59 55 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
LPS-induced glial cell activation is increased in COX-2-/- mice
###end title 35
###begin p 36
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 398 402 398 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 415 419 415 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
To determine glial cell response, we examined the expression of GFAP, a specific marker for astrocytes, and SRA, a specific marker for phagocytic microglia [36], 24 h after LPS injection, using quantitative real time PCR and immunohistochemistry. LPS markedly increased the expression of GFAP (Fig. 2A) and SRA mRNA (Fig. 2B) compared to vehicle injected mice, and the induction was higher in COX-2-/- than in COX-2+/+ mice.
###end p 36
###begin p 37
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of COX-2 deficiency on LPS-induced expression of glial markers.</bold>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFAP </italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRA </italic>
###xml 179 182 179 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 191 195 191 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 280 282 278 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 293 295 291 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 356 357 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 357 359 355 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 400 404 398 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 604 608 602 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 617 621 615 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
Effects of COX-2 deficiency on LPS-induced expression of glial markers. Quantitative real time-PCR analysis of astrocyte marker GFAP (A) and microglia marker SRA mRNA (B) in COX-2+/+and COX-2-/- mice 24 h after icv injection of LPS or vehicle. Data are presented as mean +/- SEM (n = 4-6). ***P < 0.001 compared to the corresponding vehicle-injected mice; #P < 0.05 compared to the LPS-injected COX-2+/+ mice. (C) Effects of COX-2 deficiency on LPS-induced activation of microglia. Representative photomicrographs of SRA immunohistochemistry in the striatum/caudate putamen and hippocampal area for COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. Bars represent 100 mum.
###end p 37
###begin p 38
###xml 72 76 72 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 85 89 85 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 369 372 369 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 399 403 399 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
Then we determined the immunoreactivity to SRA. In vehicle-treated COX-2+/+ and COX-2-/- mice, no SRA immunoreactivity was seen (Fig. 2C). Intense immunoreactive SRA-positive microglia with enhanced staining intensity, enlarged cell bodies, and thickening of processes were observed 24 h after LPS injection in the cortical/caudate putamen and hippocampal area of COX-2+/+mice. In LPS-injected COX-2-/- mice, SRA-positive cells were numerous with higher cells retaining an enlarged cell body with thickening of ramified processes (Fig. 2C).
###end p 38
###begin title 39
###xml 60 64 60 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Expression of cytokines and chemokines is increased in COX-2-/- mice after LPS
###end title 39
###begin p 40
###xml 225 227 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 241 243 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 261 263 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 293 295 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3E</xref>
###xml 315 319 293 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 328 332 306 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 406 409 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 426 430 404 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 441 445 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A&#8211;C</xref>
###xml 450 452 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3E</xref>
###xml 534 536 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 615 619 587 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 628 632 600 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 678 682 650 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 693 695 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 812 815 776 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 832 836 796 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 884 888 842 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 944 948 900 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 999 1002 949 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1056 1060 1004 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 836 840 <span type="species:ncbi:10090">mice</span>
The expression of cytokine and chemokine genes, such as TNF-alpha, IL-6, IL-1beta, MIP-1alpha/CCL3, MCP-1/CCL2, was determined quantitatively using real time PCR. LPS significantly increased the expression of TNF-alpha (Fig. 3A), IL-6 (Fig. 3B), IL-1beta (Fig. 3C), MIP-1alpha and MCP-1 (Fig. 3E) mRNA in both COX-2+/+ and COX-2-/- mice. However, the mRNA levels of these cytokines were higher in the COX-2-/-compared to COX-2+/+ mice (Fig. 3A-C and 3E). IL-1beta was almost not detectable in the brain of vehicle-injected mice (Fig. 3D). Brain protein levels of IL-1beta were also increased after LPS in both COX-2+/+ and COX-2-/- mice, and the increase was higher in the COX-2-/- mice (Fig. 3D). Brain protein levels of TNF-alpha and of MIP-1alpha were also significantly increased after LPS injection in COX-2-/-compared to COX-2+/+ mice (TNF-alpha: 3.9 +/- 0.2, LPS injected COX-2-/- (n = 5) vs. 2.2 +/- 0.6 ng/g protein, LPS injected COX-2+/+ (n = 3); MIP-1alpha: 340 +/- 70, LPS injected COX-2-/-(n = 5) vs. 70 +/- 41 ng/g protein, LPS injected COX-2+/+ (n = 3), p < 0.05).
###end p 40
###begin p 41
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of COX-2 deficiency on LPS-induced expression of cytokines and chemokines.</bold>
###xml 122 132 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-&#945; </italic>
###xml 137 142 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6 </italic>
###xml 147 156 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1&#946; </italic>
###xml 190 196 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 209 213 198 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 222 226 211 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 354 358 340 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 367 370 353 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 455 457 439 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 468 470 452 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 531 532 515 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 532 534 516 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 542 544 526 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 544 546 528 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 554 557 538 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink">###</sup>
###xml 557 559 541 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 601 605 585 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
###xml 605 609 <span type="species:ncbi:10090">mice</span>
Effects of COX-2 deficiency on LPS-induced expression of cytokines and chemokines. Quantitative real time-PCR analysis of TNF-alpha (A), IL-6 (B), IL-1beta (C), and CCL3/MIP-1alpha and CCL2/MCP-1 (E) for COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. (D) ELISA-based quantification of IL-1beta protein levels in the brain of COX-2+/+ and COX-2-/-mice 24 h after icv injection of LPS or vehicle. Data are presented as mean +/- SEM (n = 4-6). ***P < 0.001 compared to the corresponding vehicle-injected mice; #P < 0.05, ##P < 0.01, ###P < 0.001 compared to the LPS-injected COX-2+/+ mice.
###end p 41
###begin title 42
###xml 48 52 48 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
mRNA expression of mPGES-1 is increased in COX-2-/- mice after LPS
###end title 42
###begin p 43
###xml 121 125 121 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 147 151 147 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 184 186 184 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 256 260 256 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 272 276 272 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 418 422 418 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 476 480 472 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 604 608 596 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 763 767 755 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 776 780 768 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 921 925 913 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 397 402 <span type="species:ncbi:10090">mouse</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 780 784 <span type="species:ncbi:10090">mice</span>
###xml 925 929 <span type="species:ncbi:10090">mice</span>
Brain mRNA levels of mPGES-1 were significantly increased by LPS, but the induction was significantly higher in the COX-2-/- mice compared to COX-2+/+ mice (Fig. 4A). In contrast, cPLA2 mRNA expression was increased by LPS to a similar extent in both COX-2+/+ and in COX-2-/- mice (Fig. 4B). COX-1 protein (Fig. 4C and 4D) and mRNA levels were not significantly changed by either LPS treatment or mouse genotype (COX-2+/+ mice: 0.8 +/- 0.03 LPS vs. 1.0 +/- 0.07 vehicle; COX-2-/- mice: 1.5 +/- 0.41 LPS vs. 0.9 +/- 0.07 vehicle; p > 0.05), suggesting that the enhanced neuroinflammatory response in COX-2-/- mice is not mediated by a compensatory induction in COX-1 after LPS. The expression of cPGES and mPGES-2 mRNA was not significantly different between COX-2+/+ and COX-2-/- mice after LPS injection (data not shown), suggesting that these enzymes are not involved in the enhanced neuroinflammatory response of COX-2-/- mice at the time point examined.
###end p 43
###begin p 44
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of COX-2 deficiency on LPS-induced expression of enzymes involved in the arachidonic acid cascade.</bold>
###xml 146 154 146 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mPGES-1 </italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cPLA</italic>
###xml 166 168 166 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 181 185 181 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 194 198 194 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 412 416 412 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 425 429 425 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 514 516 512 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 527 529 525 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 590 591 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 591 593 589 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 634 638 632 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
Effects of COX-2 deficiency on LPS-induced expression of enzymes involved in the arachidonic acid cascade. Quantitative real time-PCR analysis of mPGES-1 (A) and cPLA2 (B) for COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. (C) Quantification of COX-1 protein levels, relative to GAPDH internal loading control in the whole brain. (D) Representative immunoblot of COX-1 expression in COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. Data are presented as mean +/- SEM (n = 4-6). ***P < 0.001 compared to the corresponding vehicle-injected mice; #P < 0.05 compared to the LPS-injected COX-2+/+ mice.
###end p 44
###begin title 45
###xml 78 82 78 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Expression of reactive oxygen species generating enzymes is increased in COX-2-/- mice after LPS
###end title 45
###begin p 46
###xml 214 218 214 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 328 332 328 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 399 403 399 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 480 485 480 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 510 515 510 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 652 656 652 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 710 715 710 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 723 728 723 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 743 747 743 747 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 765 767 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 835 840 835 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 871 875 871 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 901 905 901 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5E</xref>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 656 660 <span type="species:ncbi:10090">mice</span>
###xml 747 751 <span type="species:ncbi:10090">mice</span>
###xml 875 879 <span type="species:ncbi:10090">mice</span>
###xml 905 909 <span type="species:ncbi:10090">mice</span>
iNOS and NADPH oxidase are major sources of reactive oxygen species during the inflammatory process, and both are expressed in glial cells. We examined gene and protein expression of ROS-generating enzymes in COX-2-/- mice 24 h after LPS injection using quantitative real time-PCR and Western blotting. In response to LPS, COX-2-/- mice showed a higher increase in iNOS mRNA levels compared to COX-2+/+ mice (Fig. 5A). Similarly, mRNA levels of NADPH oxidase cytosolic subunit p67phox and membrane subunit gp91phox were significantly elevated at 24 h after LPS injection in both genotypes compared with vehicle-injected controls (Fig. 5B and 5C). COX-2-/- mice showed a higher increase in the expression of p67phox and gp91phox mRNA than COX-2+/+ mice (Fig. 5B and 5C). Western blotting analysis confirmed that protein level of the p67phox subunit was higher in the COX-2-/- mice compared to the COX-2+/+ mice after LPS (Fig. 5D and 5E).
###end p 46
###begin p 47
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of COX-2 deficiency on LPS-induced expression of ROS-generating enzymes.</bold>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">iNOS </italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gp91</italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">phox </italic>
###xml 134 139 134 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>phox </italic></sup>
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(</italic>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p67</italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">phox </italic>
###xml 150 155 150 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>phox </italic></sup>
###xml 173 177 173 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 186 190 186 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 289 294 289 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 409 414 409 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 433 437 433 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 446 450 446 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 535 537 533 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 548 550 546 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 611 612 609 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 612 614 610 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 622 624 620 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 624 626 622 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 667 671 665 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 605 609 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
Effects of COX-2 deficiency on LPS-induced expression of ROS-generating enzymes. Quantitative real time-PCR analysis of iNOS (A), gp91phox (B) and p67phox mRNA (C) for COX-2+/+ and COX-2-/- mice that received icv injection of LPS or vehicle 24 h before sacrifice. (D) Quantification of p67phox protein levels, relative to GAPDH internal loading control in the whole brain. (E) Representative immunoblot of p67phox expression in COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. Data are presented as mean +/- SEM (n = 4-6). ***P < 0.001 compared to the corresponding vehicle-injected mice; #P < 0.05, ##P < 0.01 compared to the LPS-injected COX-2+/+ mice.
###end p 47
###begin title 48
###xml 109 113 105 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Phosphorylated STAT3 and the mRNA expression of STAT3 and SOCS3, but not of NF-kappaB, are increased in COX-2-/- mice after LPS
###end title 48
###begin p 49
###xml 150 152 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 304 306 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 427 431 423 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 520 522 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 556 560 544 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 569 573 557 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 742 746 730 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 757 759 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 764 766 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 819 823 807 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 841 845 829 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 950 952 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 957 959 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6E</xref>
###xml 1092 1096 1080 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1107 1109 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 1114 1116 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6E</xref>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 746 750 <span type="species:ncbi:10090">mice</span>
###xml 823 827 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10090">mice</span>
###xml 939 943 <span type="species:ncbi:10090">mice</span>
###xml 1096 1100 <span type="species:ncbi:10090">mice</span>
Activation of the transcription factors NF-kappaB and STAT3 plays a critical role in the production of inflammatory mediators by activated microglia [12]. STAT signaling is tightly regulated by its negative regulators, suppressors of cytokine signaling (SOCS), and is controlled by STAT phosphorylation [37]. To determine the transcriptional mechanism underlying the increased inflammatory response to LPS observed in the COX-2-/- mice, we examined NF-kappaB p65 and STAT3 levels. The mRNA expression of NF-kappaB (Fig. 6A) was increased similarly in COX-2+/+ and COX-2-/- mice after LPS. The expression of STAT3 and SOCS3 mRNA was also significantly increased 24 h after LPS injection in both genotypes compared to the vehicle-injected COX-2+/+ mice (Fig. 6B and 6C), but the increase was significantly higher in COX-2-/- mice than in COX-2+/+ mice. Phosphorylated STAT3 was not detected in the brain nuclear fraction of vehicle-injected mice (Fig. 6D and 6E); however, after LPS, phosphorylated STAT3 protein level increased in both genotypes, but was increased to a greater extent in COX-2-/- mice (Fig. 6D and 6E).
###end p 49
###begin p 50
###xml 0 110 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of COX-2 deficiency on LPS-induced expression of transcription factors NF-&#954;B and STAT3, and SOCS3.</bold>
###xml 150 160 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF-&#954;B </italic>
###xml 165 171 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOCS3 </italic>
###xml 179 185 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3 </italic>
###xml 203 207 195 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 216 220 208 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 457 461 449 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 470 474 462 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 559 561 549 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 570 572 560 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 582 584 572 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 595 597 585 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 658 660 648 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 660 662 650 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 703 707 693 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
Effects of COX-2 deficiency on LPS-induced expression of transcription factors NF-kappaB and STAT3, and SOCS3. Quantitative real time-PCR analysis of NF-kappaB (A), SOCS3 (B) and STAT3 mRNA (C) for COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. (D) Quantification of phosphorylated STAT3 (Tyr 705) protein levels, relative to the total STAT3 in the brain nuclear fraction. (E) Representative immunoblot of P-STAT3 expression in COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. Data are presented as mean +/- SEM (n = 4-6). *P < 0.05, **P < 0.01, ***P < 0.001 compared to the corresponding vehicle-injected mice; ##P < 0.01 compared to the LPS-injected COX-2+/+ mice.
###end p 50
###begin title 51
###xml 21 25 21 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 126 130 123 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox</sup>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Pretreatment of COX-2+/+ mice with celecoxib for 6 weeks increases LPS-induced brain IL-1beta level, NADPH oxidase subunit p67phox, and phosphorylated STAT3
###end title 51
###begin p 52
###xml 90 94 90 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 138 142 138 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 220 224 216 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 297 301 289 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 438 440 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 468 473 457 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 479 481 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 486 488 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7D</xref>
###xml 531 533 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7E</xref>
###xml 538 540 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7F</xref>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
Brain COX-1 protein levels were not significantly changed by LPS treatment either in COX-2+/+ or in celecoxib-treated mice (Fig. 7A, COX-2+/+ mice: 0.041 +/- 0.009 LPS vs. 0.033 +/- 0.003 vehicle; celecoxib-treated COX-2+/+ mice: 0.043 +/- 0.0.008 LPS vs. 0.038 +/- 0.004 vehicle; p > 0.05). COX-2+/+ mice pretreated with celecoxib showed a significant increase in brain IL-1beta protein level after LPS, compared to untreated mice (Fig. 7B). The protein levels of p67phox (Fig. 7C and 7D) and phosphorylated STAT3 after LPS (Fig. 7E and 7F) were also higher in the celecoxib-treated mice compared to untreated mice.
###end p 52
###begin p 53
###xml 136 141 133 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 0 192 0 189 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of chronic pretreatment with celecoxib (6000 ppm for 6 weeks) on LPS-induced brain IL-1&#946; levels, the expression of COX-1, p67<sup>phox </sup>NADPH oxidase subunit and the phosphorylated STAT3.</bold>
###xml 319 323 316 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 350 354 347 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 503 507 497 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 546 551 540 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox </sup>
###xml 709 713 703 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 937 941 931 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 996 998 988 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1007 1009 999 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1020 1022 1012 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1083 1084 1075 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1084 1086 1076 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1094 1097 1086 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink">###</sup>
###xml 1097 1099 1089 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1141 1145 1133 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 354 358 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
###xml 941 945 <span type="species:ncbi:10090">mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
###xml 1145 1149 <span type="species:ncbi:10090">mice</span>
Effects of chronic pretreatment with celecoxib (6000 ppm for 6 weeks) on LPS-induced brain IL-1beta levels, the expression of COX-1, p67phox NADPH oxidase subunit and the phosphorylated STAT3. (A) Representative immunoblot of COX-1 protein levels, relative to GAPDH internal loading control, in the whole brain of COX-2+/+ and celecoxib-treated COX-2+/+ mice 24 h after icv injection of LPS or vehicle. (B) ELISA based immunoassay for brain IL-1beta in celecoxib-treated mice (n = 7) and untreated COX-2+/+ mice (n = 4). (C) Quantification of p67phox protein levels, relative to GAPDH internal loading control in the whole brain with representative immunoblot (D) in celecoxib-treated mice and untreated COX-2+/+ mice (n = 4). (E) Quantification of phosphorylated STAT3 (Tyr 705) protein levels, relative to the total STAT3 in the brain nuclear fraction and the representative immunoblot (F) in celecoxib-treated mice and untreated COX-2+/+ mice (n = 4). All data are expressed as mean +/- SEM. *P <0.05, **P < 0.01, ***P < 0.001 compared to the corresponding vehicle-injected mice; #P < 0.05, ###P < 0.001 compared to the LPS-injected COX-2+/+ mice.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 515 519 512 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">phox</sup>
###xml 709 711 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 831 833 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 911 914 905 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 946 948 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1236 1238 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1074 1080 <span type="species:ncbi:9606">humans</span>
In this study we demonstrate for the first time that genetic deletion of COX-2 enhanced the neuroinflammatory response and increased the susceptibility to neuronal damage induced by centrally injected LPS. We also showed that chronic treatment with a selective COX-2 inhibitor, celecoxib, also increases LPS-induced protein levels of IL-1beta, a major proinflammatory cytokine, of phosphorylated STAT3, a transcription factor involved in the progression of the inflammatory cascade, and of NADPH oxidase subunit p67phox, a marker of oxidative stress. We have previously demonstrated that this chronic dosing paradigm of celecoxib (6000 ppm for 6 weeks) leads to a plasma concentration of 18.2 +/- 5.8 mug/ml [28]. Assuming 98% binding of celecoxib to plasma proteins and that only free celecoxib can cross the blood brain barrier [38], brain concentration of celecoxib is approximately 640 nM, well above the IC50 (39 nM) of celecoxib for COX-2 [28]. These plasma concentrations are within the same order of magnitude of steady state concentrations (2-3 mug/ml) observed in humans after acute administration of 400-800 mg of celecoxib, doses clinically used for the treatment of rheumatoid arthritis and familial adenomatous polyposis [39].
###end p 55
###begin p 56
###xml 67 71 67 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1275 1277 1275 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1712 1716 1712 1716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 1760 1762 1760 1762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1879 1881 1879 1881 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1888 1889 1888 1889 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1982 1984 1982 1984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
In this study, FJB-positive neurons were only observed in the COX-2-/- mice, suggesting that COX-2 deletion increases the susceptibility to LPS-induced neurodegeneration. There is a conflicting view about the role of COX-2 in neurodegeneration and neurotoxicity [40]. For instance, COX-2 inhibition is believed to be neuroprotective in models such as MPTP (1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine), quisquallic acid induced damage [41,42], and centrally injected NMDA-induced neurotoxicity [43,44]. However, in these studies, where the toxins directly damage neurons, COX-2-mediated cytotoxicity does not appear to be linked to the inflammatory response [41]. On the other hand, pre-treatment with COX-2 inhibitors or genetic deletion of COX-2 has been shown to increase seizure activity and neuronal damage in response to kainate [28,45], and to exacerbate endotoxin-induced ocular inflammation [46] and tissue damage in ConA- and acetaminophen-induced hepatotoxicity [47,48]. Another study reported, in support of our observations, that selective pharmacological inhibition of COX-2 with NS-398 increases the transcription of inflammatory genes (mPGES-1, TLR2, CD14, MCP-1) in vascular associated brain cells and parenchymal microglia after systemic injection of LPS [14]. While these conflicting data highlight the importance of investigating the distinct roles of COX-1 and COX-2 in physiology and pathology, our findings suggest that COX-2-derived products selectively mediate a protective effect in the development and/or the resolution of inflammation in the brain after endotoxin activation of the innate immune system. In this regard, a recent review emphasizes that COX-2 mediates neuroprotection via specific anti-inflammatory lipid mediators [49]. Furthermore, Gilroy and colleagues demonstrated that selective COX-2 inhibitors, by blocking the production of PGE2 and PGD2, disturbed the resolution phase of inflammation, leading to delay in return to homeostasis [50].
###end p 56
###begin p 57
###xml 74 78 74 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 121 125 121 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 439 443 439 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 811 815 811 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
###xml 815 819 <span type="species:ncbi:10090">mice</span>
COX-1 protein levels were not significantly changed by LPS in either COX-2-/- or celecoxib-treated mice compared to COX-2+/+ mice, indicating that the increased neuroinflammatory response was not due to an increased compensatory expression of COX-1 in response to LPS when COX-2 is either genetically abrogated or pharmacologically inhibited. Increases in microglial activation and in the induction of cytokines and chemokines in the COX-2-/- mice could contribute to the susceptibility to LPS-induced damage. Overexpression of chemokines, small pleiotropic chemoattractant cytokines that promote leukocytes activation and migration, has been recently implicated in many neurological disorders including multiple sclerosis, and Alzheimer's disease [51,52]. The overexpression of chemokines observed in the COX-2-/- mice after LPS may increase the leukocytes and monocytes recruitment in the inflamed brain and cause neuronal damages, in the absence of a "switch off" mechanism. The increased expression of cytokines could be due to the incapacity of the tissue to resolve the inflammation, leading to a persistent activation of the inflammatory cascade. One possibility is that COX-2 deletion or inhibition leads to a reduction in anti-inflammatory mediators or neurotrophic factors, which would impair the brain ability to resolve the inflammation.
###end p 57
###begin p 58
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 437 446 430 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 447 449 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 514 516 507 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 550 552 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
iNOS and NADPH oxidase may also contribute to microglia-mediated LPS induced neurotoxicity by increasing the production of extracellular reactive oxygen and nitrogen species, which, in turn, stimulate the microglial release of pro-inflammatory mediators that, like radical oxygen species, are toxic to neurons [53,54]. In this regard, NADPH inhibitors suppress LPS-induced expression of iNOS, IL-6, IL-1beta and TNF-alpha in glial cells in vitro [55] and NADPH oxidase has been shown to regulate COX-2 mediated PGE2 production in cultured microglia [56].
###end p 58
###begin p 59
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 390 394 386 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 403 407 399 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 544 548 540 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 620 624 616 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 646 650 642 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 732 734 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 812 814 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 815 817 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 1059 1061 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1153 1157 1145 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 548 552 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 650 654 <span type="species:ncbi:10090">mice</span>
###xml 868 872 <span type="species:ncbi:10090">mice</span>
###xml 954 958 <span type="species:ncbi:10090">mice</span>
###xml 1157 1161 <span type="species:ncbi:10090">mice</span>
The JAK/STAT pathway is a key player in the intracellular response to cytokines. SOCS3 is a potent inhibitor of the JAK/STAT signaling cascade, negatively regulating signal transduction pathways mediated by a variety of cytokines. SOCS3 has been suggested to play a critical role in integrating the neuroimmunoendocrine circuits [57]. Although NF-kappaB p65 expression were similar in COX-2+/+ and COX-2-/- mice after LPS, we found that the mRNA expression of STAT3 and the levels of phosphorylated STAT-3 were significantly higher in the COX-2-/- mice compared to wild type mice. SOCS3 was also upregulated in the COX-2-/- mice compared to COX-2+/+ mice after LPS. SOCS3 is a negative modulator of inflammatory cytokine signaling [58] and can be induced by inflammatory stimuli such as LPS, TNF-alpha and IL-6 [58,59]. SOCS3 mRNA up-regulation in the COX-2 deficient mice can thus be viewed as the consequence of the higher cytokine production in these mice after LPS. In this regard, SOCS3 overexpression has been shown to lead to neuroblastoma cell death [60]. Overall, our data indicate a dysregulation of the cytokine signaling pathway in the COX-2-/- mice, which may mediate the increased neuroinflammatory response.
###end p 59
###begin p 60
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1041 1043 1041 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1044 1046 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
While independent epidemiological studies indicate that non steroidal anti-inflammatory drugs (NSAIDs) administration prevents or delays the onset and risk of developing Alzheimer's disease [61-63], clinical trials using COX-2 selective inhibitors in patients with mild to severe cognitive impairment, have been unsuccessful to date [64-67], with the exception of a small double blind, placebo-controlled study with indomethacin, a preferential COX-1 inhibitor [68]. We have recently demonstrated that genetic deletion or pharmacological inhibition of COX-1 significantly attenuates glial cells activation and the neuroinflammatory response, oxidative stress and neuronal damage in response to icv injected LPS [12]. Our results show that while COX-1 selective inhibition may be beneficial, selective inhibition of COX-2 appears not to be beneficial in neurodegenerative diseases with a marked inflammatory component and may explain the failure of selective COX-2 inhibitors to protect AD patients from cognitive decline in clinical trials [64-67].
###end p 60
###begin title 61
Conclusion
###end title 61
###begin p 62
These findings altogether indicate that the two COX isoforms display opposite roles in the brain during the acute neuroinflammatory process and that COX-2 inhibition worsens the inflammatory response to LPS, suggesting a neuroprotective function of COX-2-derived products. In this regard, further investigations are warranted to identify which specific COX-2 products may mediate the neuroprotective effects and more research should be focused on COX-1 selective inhibitors for the treatment of neurological and neurodegenerative diseases with an inflammatory component.
###end p 62
###begin title 63
Abbreviations
###end title 63
###begin p 64
###xml 722 723 707 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 740 741 725 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 746 747 731 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 764 765 749 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 770 771 755 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 788 789 773 774 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 59 65 <span type="species:ncbi:9913">bovine</span>
AD: Alzheimer's disease; ANOVA: analysis of variance; BSA: bovine serum albumin; COX: cyclooxygenase; CNS: central nervous system; DAB: 3,3-diaminobenzidine tetrachloride; ELISA: enzyme linked immunosorbent assay; GAPDH: glyceraldehyde dehydrogenase; GFAP: glial fibrillary acidic protein; icv: intracerebroventricular; IL-1beta: interleukin1 beta; IL-6: interleukin 6; iNOS: inducible nitric oxide synthase; JAK: Janus kinase; LPS: lipopolysaccharide; MCP-1: monocyte chemoattractant protein-1; MIP-1alpha: macrophage inflammatory protein 1 alpha; mPGES-1 or -2: microsomal prostaglandin E synthase-1 or -2; cPGES: cytosolic prostaglandin E synthase; NF-kappaB: nuclear factor- kappaB; PBS: phosphate-buffered saline; PGD2: prostaglandin D2; PGE2: prostaglandin E2; PLA2: phospholipase A2; ROS: reactive oxygen species; SOCS3: suppressors of cytokine signaling 3; SRA: scavenger receptor A; STAT3: signal transducer and activator of transcription 3; TNF-alpha: Tumor Necrosis Factor alpha.
###end p 64
###begin title 65
Competing interests
###end title 65
###begin p 66
The authors declare that they have no competing interests.
###end p 66
###begin title 67
Authors' contributions
###end title 67
###begin p 68
###xml 123 127 123 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
SA performed the experiments, contributed to study design and data analysis and wrote the manuscript. RL provided the COX-2+/+ and COX-2-/-mice and reviewed the manuscript. FB directed the work, contributed to study design, reviewed the data, and wrote the manuscript. All authors read and approved the final manuscript.
###end p 68
###begin title 69
Acknowledgements
###end title 69
###begin p 70
This work was supported by the Intramural Research Programs of the National Institute on Aging and the National Institute of Environmental Health Sciences, National Institutes of Health. We thank Drs. Sang-Ho Choi and Christopher D. Toscano for useful experimental suggestions and discussion and Dr. Alan B. Zonderman for statistical help.
###end p 70
###begin article-title 71
Distinct functions of COX-1 and COX-2
###end article-title 71
###begin article-title 72
Cyclooxygenases and the central nervous system
###end article-title 72
###begin article-title 73
Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids
###end article-title 73
###begin article-title 74
###xml 48 51 <span type="species:ncbi:10116">rat</span>
Characterization of inducible cyclooxygenase in rat brain
###end article-title 74
###begin article-title 75
Prostaglandins and sleep
###end article-title 75
###begin article-title 76
Role of COX-2 in inflammatory and degenerative brain diseases
###end article-title 76
###begin article-title 77
###xml 98 101 <span type="species:ncbi:10116">rat</span>
COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex
###end article-title 77
###begin article-title 78
Modulatory role of cyclooxygenase-2 in cerebrovascular coupling
###end article-title 78
###begin article-title 79
The role of arachidonic acid and its metabolites in the release of neuropeptides
###end article-title 79
###begin article-title 80
Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death
###end article-title 80
###begin article-title 81
Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders
###end article-title 81
###begin article-title 82
Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury
###end article-title 82
###begin article-title 83
###xml 113 117 <span type="species:ncbi:10090">mice</span>
The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(-/-), but not in cyclooxygenase-1(-/-) mice
###end article-title 83
###begin article-title 84
Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli
###end article-title 84
###begin article-title 85
###xml 15 21 <span type="species:ncbi:10090">murine</span>
Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by alpha- or gamma-tocopherol
###end article-title 85
###begin article-title 86
Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo
###end article-title 86
###begin article-title 87
###xml 162 166 <span type="species:ncbi:10090">mice</span>
Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice
###end article-title 87
###begin article-title 88
###xml 87 90 <span type="species:ncbi:10116">rat</span>
The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during a lipopolysaccharide-induced model of central nervous system inflammation
###end article-title 88
###begin article-title 89
Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent
###end article-title 89
###begin article-title 90
Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway
###end article-title 90
###begin article-title 91
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
Bacterial endotoxin induces STAT3 activation in the mouse brain
###end article-title 91
###begin article-title 92
Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide
###end article-title 92
###begin article-title 93
Chemokines - chemotactic cytokines that mediate inflammation
###end article-title 93
###begin article-title 94
###xml 138 143 <span type="species:ncbi:10090">mouse</span>
Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum
###end article-title 94
###begin article-title 95
The impact of systemic infection on the progression of neurodegenerative disease
###end article-title 95
###begin article-title 96
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
###end article-title 96
###begin article-title 97
###xml 89 94 <span type="species:ncbi:10090">mouse</span>
Differential gene expression patterns in cyclooxygenase-1 and cyclooxygenase-2 deficient mouse brain
###end article-title 97
###begin article-title 98
###xml 140 144 <span type="species:ncbi:10090">mice</span>
Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice
###end article-title 98
###begin article-title 99
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
Toll-like receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse model of LPS-induced CNS inflammation
###end article-title 99
###begin article-title 100
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
###end article-title 100
###begin article-title 101
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
Prostaglandin E2 and microsomal prostaglandin E synthase-2 expression are decreased in the cyclooxygenase-2-deficient mouse brain despite compensatory induction of cyclooxygenase-1 and Ca2+-dependent phospholipase A2
###end article-title 101
###begin article-title 102
Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis
###end article-title 102
###begin article-title 103
###xml 92 95 <span type="species:ncbi:10116">rat</span>
Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging
###end article-title 103
###begin article-title 104
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
###end article-title 104
###begin article-title 105
Diverse microglial responses after intrahippocampal administration of lipopolysaccharide
###end article-title 105
###begin article-title 106
Signalling pathways mediating inflammatory responses in brain ischaemia
###end article-title 106
###begin article-title 107
###xml 72 78 <span type="species:ncbi:9606">humans</span>
Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans
###end article-title 107
###begin article-title 108
Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor
###end article-title 108
###begin article-title 109
###xml 96 101 <span type="species:ncbi:10090">mouse</span>
Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models
###end article-title 109
###begin article-title 110
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
###end article-title 110
###begin article-title 111
Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease
###end article-title 111
###begin article-title 112
###xml 126 130 <span type="species:ncbi:10090">mice</span>
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice
###end article-title 112
###begin article-title 113
Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration
###end article-title 113
###begin article-title 114
Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus
###end article-title 114
###begin article-title 115
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Endotoxin-induced uveitis in cyclooxygenase-2-deficient mice
###end article-title 115
###begin article-title 116
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury
###end article-title 116
###begin article-title 117
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Expression profiling of acetaminophen liver toxicity in mice using microarray technology
###end article-title 117
###begin article-title 118
Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways
###end article-title 118
###begin article-title 119
Inducible cyclooxygenase may have anti-inflammatory properties
###end article-title 119
###begin article-title 120
Chemokines and their receptors in the central nervous system
###end article-title 120
###begin article-title 121
Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?
###end article-title 121
###begin article-title 122
Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism
###end article-title 122
###begin article-title 123
NADPH oxidase
###end article-title 123
###begin article-title 124
Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma
###end article-title 124
###begin article-title 125
Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia
###end article-title 125
###begin article-title 126
The central role of SOCS-3 in integrating the neuro-immunoendocrine interface
###end article-title 126
###begin article-title 127
Negative regulation of cytokine and TLR signalings by SOCS and others
###end article-title 127
###begin article-title 128
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages
###end article-title 128
###begin article-title 129
JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3
###end article-title 129
###begin article-title 130
Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
###end article-title 130
###begin article-title 131
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease
###end article-title 131
###begin article-title 132
Risk of Alzheimer's disease and duration of NSAID use
###end article-title 132
###begin article-title 133
Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease
###end article-title 133
###begin article-title 134
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial
###end article-title 134
###begin article-title 135
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study
###end article-title 135
###begin article-title 136
###xml 50 58 <span type="species:ncbi:9606">patients</span>
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment
###end article-title 136
###begin article-title 137
Clinical trial of indomethacin in Alzheimer's disease
###end article-title 137

